Lilly CEO: Realistic Expectations Needed For Current Wave of Alzheimer’s Treatments
Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.
You may also be interested in...
More long-term data for donanemab needed, FDA says. Lilly plans to seek traditional approval for its amyloid-clearing antibody after the Phase III TRAILBLAZER-ALZ 2 trial reads out in Q2, but it loses important ground in reimbursement negotiations.
Scrip has taken a look back at five of the biggest story themes in no particular order of 2022 where once again the biopharma industry had plenty on its plate.
Infographic compares pivotal trials for Alzheimer's disease-modifying candidates from Biogen/Eisai, Lilly and Roche.